Show Summary Details
Page of

Advances in Intrathecal Drug Delivery: Impact on Orthopedic Practice 

Advances in Intrathecal Drug Delivery: Impact on Orthopedic Practice
Chapter:
Advances in Intrathecal Drug Delivery: Impact on Orthopedic Practice
Author(s):

Jay S. Grider

, Michael E. Harned

, and Vital Nagar

DOI:
10.1093/med/9780190626761.003.0018
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 11 December 2019

Intrathecal drug delivery has become a commonplace means to treat recalcitrant chronic pain of malignant and nonmalignant origins. Although intrathecal drug delivery systems (IDDS) and intrathecal drug delivery (IDD) itself rapidly established themselves in the treatment of malignant pain at the end of life, these therapies are also utilized for treatment of pain of nonmalignant origin. While the only US Food and Drug Administration (FDA)-approved medications for use in the intrathecal space are morphine, baclofen, and ziconotide, this chapter will also address commonly used medications such as clonidine and local anesthetics such as bupivacaine as well. While this chapter serves as general overview of the topic’s long history and rapidly developing literature, a basic understanding of the modality and medications used is important.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.